These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9401351)

  • 21. Vascular tumor growth and treatment: consequences of polyclonality, competition and dynamic vascular support.
    Jackson TL
    J Math Biol; 2002 Mar; 44(3):201-26. PubMed ID: 12148489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal chemical control of populations developing drug resistance.
    Costa MI; Boldrini JL; Bassanezi RC
    IMA J Math Appl Med Biol; 1992; 9(3):215-26. PubMed ID: 1295929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regrowth resistance in cancer: why has it been largely ignored?
    Preisler HD; Venugopal P
    Cell Prolif; 1995 Jun; 28(6):347-56. PubMed ID: 7626689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulation model of doxorubicin activity in islets of human breast cancer cells.
    Lankelma J; Fernández Luque R; Dekker H; Pinedo HM
    Biochim Biophys Acta; 2003 Aug; 1622(3):169-78. PubMed ID: 12928113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A delay differential equation model for tumor growth.
    Villasana M; Radunskaya A
    J Math Biol; 2003 Sep; 47(3):270-94. PubMed ID: 12955460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mathematical model of cancer chemotherapy with an optimal selection of parameters.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1990 May; 99(2):205-30. PubMed ID: 2134520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the Transfer of Drug Resistance in Solid Tumors.
    Becker M; Levy D
    Bull Math Biol; 2017 Oct; 79(10):2394-2412. PubMed ID: 28852953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Kinetics of breast neoplasms].
    Surbone A; Norton L
    Minerva Med; 1994; 85(1-2):7-16. PubMed ID: 8152580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
    de Pillis LG; Gu W; Radunskaya AE
    J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A critical appraisal of the "human tumor stem-cell assay".
    Selby P; Buick RN; Tannock I
    N Engl J Med; 1983 Jan; 308(3):129-34. PubMed ID: 6336820
    [No Abstract]   [Full Text] [Related]  

  • 31. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A minimal model of tumor growth inhibition.
    Magni P; Germani M; De Nicolao G; Bianchini G; Simeoni M; Poggesi I; Rocchetti M
    IEEE Trans Biomed Eng; 2008 Dec; 55(12):2683-90. PubMed ID: 19126447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy in heterogeneous cultures of cancer cells with interconversion.
    Dilão R
    Phys Biol; 2014 Nov; 12(1):016002. PubMed ID: 25429401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors.
    Yin A; Moes DJAR; van Hasselt JGC; Swen JJ; Guchelaar HJ
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):720-737. PubMed ID: 31250989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mathematical analysis of cancer chemotherapy: the effects of chemotherapeutic agents on the cell cycle traverse.
    Chuang SN; Soong TT
    Bull Math Biol; 1978; 40(4):499-512. PubMed ID: 678695
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs.
    Yoon N; Vander Velde R; Marusyk A; Scott JG
    Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency.
    Harnevo LE; Agur Z
    Cancer Chemother Pharmacol; 1992; 30(6):469-76. PubMed ID: 1394803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume.
    Gregory WM; Reznek RH; Hallett M; Slevin ML
    Br J Cancer; 1990 Oct; 62(4):671-5. PubMed ID: 2223589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.